Talimogene Laherparepvec
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 445 publications
ASO Visual Abstract: Evaluation of Talimogene Laherparepvec for the Treatment of Advanced Nonmelanoma Skin Cancers.
Journal: Annals of surgical oncology
Published: March 02, 2026
Neoantigen-Encoded Oncolytic Viruses as Personalized Cancer Vaccines.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: January 24, 2026
Enhanced Antitumor Activity and Induction of Immunogenic Cell Death in NUT Carcinoma Cells by Combining Oncolytic Viruses with the Dual Inhibitor NEO2734.
Journal: Viruses
Published: January 15, 2026
Oncolytic Viruses in Cancer Immunotherapy: From Molecular Engineering to Clinical Translation.
Journal: Cells
Published: January 11, 2026
Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma.
Journal: Journal for immunotherapy of cancer
Published: December 08, 2025
Opportunities and challenges in the clinical application of anticancer virotherapy.
Journal: Expert review of anticancer therapy
Published: November 01, 2025
The Evolution, Current Landscape, and Future Prospects of Oncolytic Virotherapy in Melanoma: Talimogene Laherparepvec and Beyond.
Journal: Cells
Published: September 16, 2025
Recurrent melanoma presenting as a rash: a case report.
Journal: Skin health and disease
Published: September 02, 2025
Addition of oncolytic virotherapy to clinical isolated limb perfusion for melanoma and sarcoma activates antitumor immunity.
Journal: Journal for immunotherapy of cancer
Published: August 27, 2025
Safety and feasibility of talimogene laherparepvec in peritoneal surface malignancies: Results from the TEMPO trial.
Journal: Molecular therapy. Oncology
Published: August 27, 2025
Oncolytic Herpes Simplex Virus Therapy: Latest Advances, Core Challenges, and Future Outlook.
Journal: Vaccines
Published: July 09, 2025
Quantitative habitat concentration analysis of triple negative breast cancer on MRI correlates with pathologic response to combination neoadjuvant immuno/chemotherapy.
Journal: Clinical imaging
Published: June 27, 2025
Last Updated: 04/28/2026